Paper42336655
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.
Roulleaux-Dugage M and 17 others. J Immunother Cancer, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC. Papers, record 42336655. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42336655
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lung Neoplasms | Major topic |
| Liver Neoplasms | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Immunotherapy | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Female | |
| Male | |
| Bevacizumab | |
| Tumor Microenvironment | |
| Aged | |
| Middle Aged | |
| Drug Resistance, Neoplasm |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29324807 | VEGF may contribute to macrophage recruitment and M2 polarization in the decidua. | PLoS One | 2018 | https://conductscience.org/library/papers/29324807 | PubMed |
| 2 | 34614508 | A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes. | Blood Adv | 2021 | https://conductscience.org/library/papers/34614508 | PubMed |
| 3 | 38600370 | Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/38600370 | PubMed |
| 4 | 38438735 | Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. | Nat Med | 2024 | https://conductscience.org/library/papers/38438735 | PubMed |
| 5 | 31122901 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31122901 | PubMed |
| 6 | 35090594 | Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. | Cancer Cell | 2022 | https://conductscience.org/library/papers/35090594 | PubMed |
| 7 | 30456891 | Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells. | J Cell Mol Med | 2019 | https://conductscience.org/library/papers/30456891 | PubMed |
| 8 | 33008914 | Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. | Sci Immunol | 2020 | https://conductscience.org/library/papers/33008914 | PubMed |
| 9 | 29508855 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/29508855 | PubMed |
| 10 | 29863955 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29863955 | PubMed |
| 11 | 36368318 | High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. | Cancer Cell | 2022 | https://conductscience.org/library/papers/36368318 | PubMed |
| 12 | 34626838 | IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. | J Thorac Oncol | 2022 | https://conductscience.org/library/papers/34626838 | PubMed |
| 13 | 38207030 | Deterministic reprogramming of neutrophils within tumors. | Science | 2024 | https://conductscience.org/library/papers/38207030 | PubMed |
| 14 | 33476593 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/33476593 | PubMed |
| 15 | 36862804 | Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. | Cancer Discov | 2023 | https://conductscience.org/library/papers/36862804 | PubMed |
| 16 | 29327044 | Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/29327044 | PubMed |
| 17 | 41825453 | Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial. | Lancet Oncol | 2026 | https://conductscience.org/library/papers/41825453 | PubMed |
| 18 | 32997907 | Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32997907 | PubMed |
| 19 | 28411193 | Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. | Cancer Immunol Res | 2017 | https://conductscience.org/library/papers/28411193 | PubMed |
| 20 | 27718847 | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27718847 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALK | 238 | PubTator's text mining | https://conductscience.org/library/genes/238 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| FLT1 | 2321 | PubTator's text mining | https://conductscience.org/library/genes/2321 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42336655
GET https://conductscience.org/api/papers/v1/42336655/references?page=2